NIPH Clinical Trials Search

JRCT ID: jRCT2041200093

Registered date:27/01/2021

A study to test the safety and tolerability of brivaracetam in pediatric study participants with seizures

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedEpilepsy
Date of first enrollment11/03/2021
Target sample size79
Countries of recruitmentBEL,Japan,CZE,Japan,FRA,Japan,DEU,Japan,HUN,Japan,ITA,Japan,IRL,Japan,MEX,Japan,POL,Japan,ESP,Japan,GBR,Japan,USA,Japan
Study typeInterventional
Intervention(s)Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses. Tablets Concentration: 10 mg, 25 mg, 50 mg Route of administration: oral Oral solution Concentration: 10 mg/ml Route of administration: oral


Primary Outcome1. Incidence of treatment-emergent adverse events (TEAEs) during the study 2. Incidence of treatment-emergent serious adverse events (SAEs) during the study 3. Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 1month old
Age maximum<= 15age old
Include criteriaInclusion criteria for long-term follow-up (LTFU) study participants only - Study participants >=1 month of age with a confirmed diagnosis of epilepsy who participated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439] and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected Inclusion criteria for directly enrolled (DE) study participants only - Study participant is >= 4 years to < 16 years of age - Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years - Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED) - Study participant had at least 1 POS during the 4-week Screening Period - Study participant is taking at least 1 AED. Vagal nerve stimulator will be counted as a concomitant AED
Exclude criteriaExclusion criteria for all study participants - Study participant has, in the Investigator's opinion, severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant. - Study participant has end-stage kidney disease requiring dialysis or any medical condition including chronic liver disease (Child Pugh Score A, B, or C), which in the Investigator's opinion, warrants exclusion - Study participant is currently participating in another study of an investigational medication (or a medical device) other than brivaracetam (BRV). The use of antiepileptic drugs (AEDs) marketed for adults but not approved for pediatric use is not considered to be "investigational" for the purposes of this study - Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates participation in the study Exclusion criteria for long-term follow-up (LTFU) study participants only - Study participant had poor compliance with the visit schedule or medication intake in the BRV core study - Study participant >= 6 years of age has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS) Exclusion criteria for directly enrolled (DE) study participants only - Study participant has a history of primary generalized epilepsy - Study participant has a history of status epilepticus in the 30 days immediately prior to the Screening Visit (ScrV) or during the Screening Period - Study participant has history or presence of known psychogenic nonepileptic seizures - Study participant has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to other unprovoked seizures is not exclusionary - Study participant has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow suppression, chronic hepatic disease, severe renal impairment, psychiatric disorder as per Investigator assessment) - Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator - Study participant has a clinically significant ECG abnormality according to the Investigator - Study participant had major surgery within 6 months prior to the ScrV

Related Information


Public contact
Name Global Clinical Science &amp; Operation
Address 8-17-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023 Tokyo Japan 160-0023
Telephone +81-3-6864-7587
Affiliation UCB Japan Co., Ltd.
Scientific contact
Name Cai Weihua
Address Sumitomo ShinToranomon Bldg. 4-3-9 Toranomon, Minato-ku, Tokyo 105-0001, Japan Tokyo Japan 105-0001
Telephone +81-80-4782-3183
Affiliation PRA Health Sciences KK